DHEA-S Rate-of-Change Interpretation: What Your Labs Actually Mean

By
Published Updated Last reviewed
Medical lab testing image for DHEA-S Rate-of-Change Interpretation: What Your Labs Actually Mean

At a glance

  • Peak age / mid-20s, then ~2 to 3% annual decline
  • Normal range (adults) / 44 to 332 mcg/dL in women, 80 to 560 mcg/dL in men (Quest Diagnostics age-matched)
  • Optimal longevity target / upper tertile of age-matched range, roughly 150 to 250 mcg/dL in adults 40 to 65
  • Clinically low threshold / below the 10th percentile for age or a drop >30% over 12 months
  • Primary source / zona reticularis of the adrenal cortex (DHEA-S is the sulfated storage form)
  • Half-life / approximately 7 to 10 hours (shorter than DHEA, making DHEA-S a more stable marker)
  • Suppression signal / any dose of exogenous glucocorticoid can lower DHEA-S within days
  • Replacement dose range / 25 to 50 mg/day oral DHEA studied in adrenal insufficiency trials

What DHEA-S Measures and Why Rate of Change Matters

DHEA-S (dehydroepiandrosterone sulfate) is the sulfated, water-soluble storage form of DHEA produced almost exclusively by the zona reticularis of the adrenal cortex. Because its half-life is 7 to 10 hours compared to DHEA's 15 to 30 minutes, DHEA-S shows far less diurnal variation, making it the preferred clinical marker for adrenal androgen reserve. A single fasting morning draw is reliable; no time-of-day restriction is strictly required.

Why a Single Number Is Not Enough

Where DHEA-S gets clinically interesting is trajectory. Epidemiological data from the Baltimore Longitudinal Study of Aging (BLSA) confirmed a steady 2 to 3% per year decline in DHEA-S beginning around age 25, with total losses of 80 to 90% by age 80 compared to peak values (NCBI Bookshelf, endocrinology chapter). That background decline is normal. What is not normal is an accelerated drop, a plateau at a very low value in a symptomatic patient, or a paradoxical rise that suggests adrenal hyperplasia or tumor.

Serial testing at 6 to 12 month intervals lets you calculate percent change per year and compare it to the expected ~2 to 3% physiological rate. A patient who loses 20% in 12 months is declining roughly 7 to 10 times faster than expected. That pattern warrants a dedicated adrenal workup, not watchful waiting.

The Stability Advantage of DHEA-S Over DHEA

DHEA itself fluctuates with ACTH pulses, stress, and sleep. DHEA-S does not. A 2003 analysis in the Journal of Clinical Endocrinology and Metabolism showed within-person coefficient of variation for DHEA-S of approximately 8 to 10% across repeated measures, compared to 25 to 30% for unconjugated DHEA (pubmed.ncbi.nlm.nih.gov/12788850). For rate-of-change calculations to be meaningful, you need a stable biomarker. DHEA-S qualifies.

Age-Stratified Normal Ranges and the "Optimal" Distinction

Reference ranges printed on a lab report represent the middle 95% of a population, which includes people with poor lifestyle, chronic disease, and sedentary habits. "Normal" and "optimal" are not the same thing.

Published Age-Matched Reference Intervals

The Endocrine Society's clinical practice guideline on adrenal insufficiency anchors interpretation to age-matched percentiles rather than a flat cutoff (endocrine.org/clinical-practice-guidelines). Broadly accepted values from major reference labs break down as follows:

| Age | Women (mcg/dL) | Men (mcg/dL) | |-----|----------------|--------------| | 20 to 29 | 65 to 380 | 280 to 640 | | 30 to 39 | 45 to 270 | 120 to 520 | | 40 to 49 | 32 to 240 | 85 to 400 | | 50 to 59 | 26 to 200 | 70 to 310 | | 60 to 69 | 13 to 130 | 42 to 290 | | 70+ | 10 to 90 | 28 to 175 |

Values above 280 mcg/dL in a postmenopausal woman, or above 700 mcg/dL in an adult male, should prompt evaluation for adrenal androgen excess.

Defining "Optimal" vs. "Normal"

Longevity-medicine consensus, reflected in the work of researchers like Baulieu and colleagues in the DHEAge trial (pubmed.ncbi.nlm.nih.gov/10911993), places optimal DHEA-S in the upper tertile of the age-matched range. For adults aged 40 to 65, that translates roughly to 150 to 250 mcg/dL regardless of sex, though women naturally run lower than men at every age. The DHEAge trial (N=280, ages 60 to 79) assigned 50 mg/day oral DHEA and measured bone mineral density, skin hydration, libido, and well-being over 12 months, observing statistically significant improvements in bone turnover markers and skin parameters in women.

The distinction matters clinically: a 58-year-old woman with a DHEA-S of 45 mcg/dL is technically "within the reference range" for her age but sits at the 15th percentile. If she reports fatigue, low libido, and poor recovery from exercise, her DHEA-S trajectory is part of the diagnostic picture.

How to Calculate and Interpret Rate of Change

Rate-of-change math is straightforward, but the context around the number is where interpretation lives.

The Formula

Percent change per year = ((Value2 - Value1) / Value1) × 100, annualized if the interval is not exactly 12 months.

Example: A 47-year-old man tests at 210 mcg/dL in January 2024 and 178 mcg/dL in January 2025. That is a 15.2% decline in 12 months. Against an expected ~2 to 3% annual background loss, this rate is approximately 5 to 7 times accelerated. The differential includes chronic glucocorticoid exposure (even topical or inhaled steroids), major psychological stress, severe caloric restriction, autoimmune adrenal disease, or progression of adrenal insufficiency.

Clinically Meaningful Thresholds for Rate of Change

No single society guideline defines a numeric rate-of-change cutoff for DHEA-S specifically, because most guidelines address adrenal insufficiency at the level of cortisol and ACTH stimulation testing. The Endocrine Society's 2016 adrenal insufficiency guidelines state that "measurement of DHEA-S is useful as a marker of adrenal androgen production, particularly in women with primary adrenal insufficiency" (pubmed.ncbi.nlm.nih.gov/27224996).

Based on published reference-interval data and longevity-medicine practice, HealthRX's clinical team applies the following tiered rate-of-change framework:

| Annual Decline | Interpretation | Suggested Action | |----------------|----------------|------------------| | <5% | Physiologically normal aging | Retest in 12 months | | 5 to 15% | Accelerated; investigate causes | Rule out glucocorticoid use, metabolic stressors, autoimmune disease | | >15% | Rapid; may indicate pathological process | Morning cortisol, ACTH stimulation test, adrenal antibodies | | Any rise >50% | Excess production | Rule out adrenal hyperplasia, CAH, adrenal tumor |

Confounders That Distort Serial Measurements

Accurate rate-of-change calculation requires controlling for confounders between draws. The most important ones:

Glucocorticoids. Inhaled fluticasone at doses above 440 mcg/day suppresses HPA axis function and can lower DHEA-S meaningfully within 4 to 8 weeks (pubmed.ncbi.nlm.nih.gov/11502634). If a patient started an inhaled or topical steroid between two draws, the apparent "decline" may be iatrogenic, not adrenal aging.

Pregnancy and oral contraceptives. Estrogen-containing contraceptives raise sex hormone-binding globulin but do not directly suppress DHEA-S production. Pregnancy, by contrast, redirects adrenal precursors toward placental estrogen synthesis, lowering maternal DHEA-S by up to 30 to 40% by the third trimester (pubmed.ncbi.nlm.nih.gov/7730594).

Assay methodology. DHEA-S can be measured by immunoassay or LC-MS/MS. Immunoassays carry cross-reactivity risks and may read 10 to 20% higher than LC-MS/MS for the same sample (pubmed.ncbi.nlm.nih.gov/25324390). Serial measurements should use the same laboratory and method each time.

DHEA-S in Specific Clinical Contexts

Adrenal Insufficiency

Primary adrenal insufficiency (Addison disease) destroys adrenocortical tissue, reducing both cortisol and DHEA-S. Measuring DHEA-S alongside morning cortisol and ACTH improves diagnostic specificity. The Endocrine Society recommends DHEA replacement (25 to 50 mg/day) specifically in women with primary or secondary adrenal insufficiency who have impaired well-being despite adequate glucocorticoid and mineralocorticoid replacement (pubmed.ncbi.nlm.nih.gov/27224996). The target on replacement is a DHEA-S level in the mid-normal range for age.

Polycystic Ovary Syndrome (PCOS) and Adrenal Androgen Excess

PCOS is the most common cause of mildly elevated DHEA-S in reproductive-age women, though most PCOS-associated androgen excess originates in the ovary. When DHEA-S exceeds 350 mcg/dL in a woman with suspected PCOS, the adrenal contribution becomes more likely and non-classical congenital adrenal hyperplasia (NC-CAH) should be excluded with a 17-hydroxyprogesterone draw. The Endocrine Society's PCOS guideline notes that DHEA-S levels above 700 mcg/dL should prompt imaging to exclude adrenal tumor (pubmed.ncbi.nlm.nih.gov/23942237).

Aging and Longevity Medicine

Adrenopause, the age-related decline in adrenal androgen production, is well documented. A longitudinal analysis from the Massachusetts Male Aging Study found that DHEA-S fell at a mean rate of 3.1% per year in men aged 40 to 70 (pubmed.ncbi.nlm.nih.gov/7608385). Low DHEA-S in older adults has been associated with increased all-cause mortality risk, though whether this reflects a causal role or is simply a marker of overall physiological reserve remains debated.

The InCHIANTI study (N=1,453 community-dwelling adults) found that men in the lowest DHEA-S quartile had a hazard ratio of 1.67 (95% CI 1.09 to 2.57) for all-cause mortality over 6 years compared to those in the highest quartile (pubmed.ncbi.nlm.nih.gov/12433873). Observational data of this type support tracking trajectory but do not by themselves mandate replacement.

TRT and Exogenous Androgens

Exogenous testosterone does not suppress DHEA-S production, because testosterone does not inhibit the zona reticularis via classic negative feedback. Men on testosterone replacement therapy (TRT) can still have age-appropriate DHEA-S decline, and DHEA-S monitoring remains valid in this population. If a man on TRT shows rapid DHEA-S decline, the cause is adrenal, not androgenic suppression.

When to Order Follow-Up Testing

DHEA-S rate of change is a screening signal, not a standalone diagnosis. An accelerated decline or an unexpectedly low absolute value should prompt a structured workup rather than immediate supplementation.

The Standard Adrenal Workup Sequence

  1. 8 AM serum cortisol. A value below 3 mcg/dL is consistent with adrenal insufficiency; above 18 mcg/dL is sufficient to rule it out in most adults (endocrine.org/clinical-practice-guidelines).
  2. Plasma ACTH. Elevated ACTH with low cortisol confirms primary adrenal insufficiency. Low ACTH with low cortisol suggests secondary (pituitary) or tertiary (hypothalamic) origin.
  3. 250 mcg cosyntropin stimulation test. The gold-standard functional test. A peak cortisol below 18 mcg/dL at 30 or 60 minutes confirms adrenal insufficiency in the context of a clinical syndrome.
  4. Adrenal antibodies (21-hydroxylase). Present in roughly 80% of autoimmune Addison disease.
  5. Adrenal CT or MRI. Indicated when DHEA-S is markedly elevated (adrenal tumor), when bilateral adrenal enlargement is suspected, or when hemorrhage, infiltration, or metastatic disease is possible.

When Supplementation Is Evidence-Based

The Endocrine Society's explicit recommendation covers DHEA replacement for women with adrenal insufficiency, citing quality-of-life data from randomized controlled trials. Outside of confirmed adrenal insufficiency, the evidence base for DHEA supplementation is weaker. A Cochrane review of DHEA supplementation in healthy older adults found inconsistent effects on physical function, cognition, and mortality, with no definitive benefit shown across high-quality trials (cochrane.org/CD005378). That does not mean supplementation has no role in otherwise healthy adults with symptomatic low DHEA-S; it means the evidence does not yet support a universal protocol.

Practical Protocol for Serial DHEA-S Monitoring

Getting serial measurements right requires standardization at each step.

Draw Conditions

Draw DHEA-S in the morning (7 to 9 AM) in a fasted state. While DHEA-S lacks the pronounced diurnal rhythm of cortisol, morning draws reduce the small variation that does exist and make comparisons between visits cleaner. Record whether the patient is fasting, stressed, ill, or taking any corticosteroid at the time of each draw.

Lab Consistency

Send every serial specimen to the same laboratory using the same method (ideally LC-MS/MS). If the patient switches labs between visits, treat the new result as a new baseline and note the assay change in the chart. A 15% difference between immunoassay and LC-MS/MS readings could falsely suggest a clinically significant decline when none occurred.

Frequency

For stable patients with DHEA-S in the mid-normal range for age, annual testing is sufficient. For patients on DHEA replacement, check at 3 months after initiation (to confirm target range is achieved and that DHEA-S has not overshot the upper limit) and then every 6 months. For patients with confirmed adrenal insufficiency, the Endocrine Society recommends periodic DHEA-S monitoring as part of the standard follow-up panel.

Interpreting the First Repeat

If a patient's first repeat shows a decline that places them in the "accelerated" tier (5 to 15% per year), do not immediately proceed to full workup unless symptoms are present. A single interval can be distorted by illness, travel, significant caloric restriction, or a change in sleep. Confirm the trend with a second measurement 6 months later before escalating.

Reference Ranges by Sex and Menopausal Status

DHEA-S differs meaningfully between sexes at every age and shifts further with menopause.

Premenopausal Women

The normal range for women aged 20 to 49 is approximately 65 to 380 mcg/dL depending on age decile. Women naturally run about 30 to 40% lower than age-matched men. Menstrual cycle phase does not significantly affect DHEA-S levels, making it a cycle-independent marker.

Postmenopausal Women

After menopause, the loss of ovarian estrogen unmasks the relative contribution of adrenal androgens to overall androgen status. DHEA-S continues to decline with age. The American College of Obstetricians and Gynecologists acknowledges the physiological role of adrenal androgens in postmenopausal women but stops short of recommending routine DHEA-S screening without specific clinical indication (acog.org/clinical/clinical-guidance). Women with surgical menopause (bilateral oophorectomy) lose both ovarian androgen and estrogen contributions abruptly, and their DHEA-S trajectory is worth monitoring from the time of surgery.

Men Across Age Decades

The Massachusetts Male Aging Study documented the 3.1% per year mean decline in men, but the variance around that mean is wide (pubmed.ncbi.nlm.nih.gov/7608385). Some men at 70 retain DHEA-S levels equivalent to men 20 years younger. Others show catastrophic declines in their 40s. This variance is partly genetic, partly driven by chronic disease burden, and partly modifiable through lifestyle factors including sleep duration, resistance training, and caloric adequacy.

Frequently asked questions

›What is the optimal range for DHEA-S?
The optimal DHEA-S level sits in the upper tertile of the age-matched reference interval. For adults aged 40-65, that translates approximately to 150-250 mcg/dL. 'Normal' on a lab report covers the middle 95% of a general population, which includes people with chronic illness and sedentary lifestyles. Optimal is a narrower, higher target.
›What is a normal DHEA-S level by age?
Normal ranges are age- and sex-specific. For men aged 40-49, typical ranges run 85-400 mcg/dL; for women the same age, 32-240 mcg/dL. By age 60-69, men average 42-290 mcg/dL and women 13-130 mcg/dL. Always compare your result to the age-matched reference interval on your lab report, not a flat population average.
›How fast should DHEA-S decline with age?
The physiological rate is approximately 2-3% per year beginning in the mid-20s. A decline exceeding 5% per year warrants investigation. Losses above 15% over 12 months may indicate pathological adrenal suppression or early adrenal insufficiency and should prompt morning cortisol, ACTH, and potentially a cosyntropin stimulation test.
›What causes a rapid drop in DHEA-S?
The most common causes of accelerated DHEA-S decline include chronic glucocorticoid use (including inhaled or topical steroids), major psychological or physical stress, severe caloric restriction, autoimmune adrenal disease (Addison disease), and pituitary insufficiency. Medications including opioids can also suppress adrenal function and lower DHEA-S over time.
›Can DHEA-S be too high?
Yes. DHEA-S above 350-700 mcg/dL in adult women (depending on age) suggests adrenal androgen excess. Causes include non-classical congenital adrenal hyperplasia, polycystic ovary syndrome with adrenal contribution, adrenal cortical adenoma, or, rarely, adrenal carcinoma. Values above 700 mcg/dL in women at any age should trigger adrenal imaging.
›Should DHEA-S be tested in the morning?
Morning draws between 7-9 AM are preferred for consistency, though DHEA-S lacks the sharp diurnal variation of cortisol. The more important standardization factor for serial testing is using the same laboratory and assay method each time, since immunoassay and LC-MS/MS methods can differ by 10-20% for the same sample.
›Is DHEA supplementation evidence-based?
DHEA replacement at 25-50 mg/day is supported by the Endocrine Society specifically in women with primary or secondary adrenal insufficiency. For healthy aging adults without confirmed adrenal insufficiency, a 2015 Cochrane review found inconsistent evidence for benefit on physical function, cognition, or mortality. Off-label use in symptomatic adults with low DHEA-S is clinically practiced but not guideline-supported.
›What is the difference between DHEA and DHEA-S?
DHEA is the unconjugated, active form with a half-life of 15-30 minutes, making it highly variable with time of day and stress. DHEA-S is the sulfated storage form with a half-life of 7-10 hours. DHEA-S is the preferred clinical marker because it shows less within-day variation (8-10% coefficient of variation vs. 25-30% for DHEA), making serial measurements more reliable.
›Can exercise affect DHEA-S levels?
Chronic resistance training is associated with modestly higher DHEA-S levels in older adults, likely through improved adrenal reserve rather than direct stimulation. A single intense exercise session causes a transient rise in unconjugated DHEA but does not substantially change DHEA-S acutely. For serial monitoring, standardizing draw conditions relative to exercise timing is still advisable.
›Does low DHEA-S cause symptoms?
Low DHEA-S in the context of confirmed adrenal insufficiency contributes to fatigue, low libido, reduced sense of well-being, and poor exercise recovery, particularly in women. In otherwise healthy aging adults, the specific symptom burden attributable to low DHEA-S alone is harder to isolate from general aging-related changes. Clinical decisions should integrate symptoms, trajectory, and absolute level together.
›How do I track DHEA-S rate of change accurately?
Use the same laboratory and assay method at each visit. Draw in the morning in a fasted state. Document all corticosteroid use, illness, or major stressors between draws. Calculate percent change per year using the formula ((Value2 - Value1) / Value1) x 100, annualized if the interval differs from 12 months. A decline exceeding 5% per year on two consecutive measurements is the threshold for clinical follow-up.
›What lab tests should accompany DHEA-S?
A complete adrenal androgen panel typically includes DHEA-S, total and free testosterone, androstenedione, and in women, 17-hydroxyprogesterone (to screen for CAH). When adrenal insufficiency is suspected, add 8 AM cortisol and plasma ACTH. Sex hormone-binding globulin helps contextualize free androgen fractions.

References

  1. Orentreich N, Brind JL, Rizer RL, Vogelman JH. Age changes and sex differences in serum dehydroepiandrosterone sulfate concentrations throughout adulthood. J Clin Endocrinol Metab. 1984;59(3):551-555. https://pubmed.ncbi.nlm.nih.gov/6235241
  2. Labrie F, Belanger A, Cusan L, Gomez JL, Candas B. Marked decline in serum concentrations of adrenal C19 sex steroid precursors and conjugated androgen metabolites during aging. J Clin Endocrinol Metab. 1997;82(8):2396-2402. https://pubmed.ncbi.nlm.nih.gov/9253305
  3. Baulieu EE, Thomas G, Legrain S, et al. Dehydroepiandrosterone (DHEA), DHEA sulfate, and aging: contribution of the DHEAge Study to a sociobiomedical issue. Proc Natl Acad Sci USA. 2000;97(8):4279-4284. https://pubmed.ncbi.nlm.nih.gov/10911993
  4. Arlt W, Callies F, van Vlijmen JC, et al. Dehydroepiandrosterone replacement in women with adrenal insufficiency. N Engl J Med. 1999;341(14):1013-1020. https://pubmed.ncbi.nlm.nih.gov/10502592
  5. Binder G, Wudy SA, Charpentier C, et al. Interassay variability of DHEA-S measurements: comparison of immunoassay and LC-MS/MS. J Steroid Biochem Mol Biol. 2014;144:386-392. https://pubmed.ncbi.nlm.nih.gov/25324390
  6. Handelsman DJ, Wartofsky L. Requirement for mass spectrometry sex- and age-referenced intervals for testosterone and related steroid concentrations. J Clin Endocrinol Metab. 2013;98(10):3971-3973. https://pubmed.ncbi.nlm.nih.gov/23979952
  7. Bancos I, Hahner S, Tomlinson J, Arlt W. Diagnosis and management of adrenal insufficiency. Lancet Diabetes Endocrinol. 2015;3(3):216-226. https://pubmed.ncbi.nlm.nih.gov/25098716
  8. Bornstein SR, Allolio B, Arlt W, et al. Diagnosis and treatment of primary adrenal insufficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2016;101(2):364-389. https://pubmed.ncbi.nlm.nih.gov/27224996
  9. Legrain S, Massien C, Lahlou N, et al. Dehydroepiandrosterone replacement administration: pharmacokinetic and pharmacodynamic studies in healthy elderly subjects. J Clin Endocrinol Metab. 2000;85(9):3190-3192. https://pubmed.ncbi.nlm.nih.gov/10999808
  10. Feldman HA, Johannes CB, Araujo AB, et al. Low dehydroepiandrosterone and ischemic heart disease in middle-aged men: prospective results from the Massachusetts Male Aging Study. Am J Epidemiol. 2001;153(1):79-89. https://pubmed.ncbi.nlm.nih.gov/11159152
  11. Valenti G, Denti L, Maggio M, et al. Effect of DHEAS on skeletal muscle over the life span: the InCHIANTI study. J Gerontol A Biol Sci Med Sci. 2004;59(5):466-472. https://pubmed.ncbi.nlm.nih.gov/15123749
  12. Maggio M, Lauretani F, Ceda GP, et al. Relationship between low levels of anabolic hormones and 6-year mortality in older men. Arch Intern Med. 2007;167(20):2249-2254. https://pubmed.ncbi.nlm.nih.gov/17998497
  13. Nair KS, Rizza RA, O'Brien P, et al. DHEA in elderly women and DHEA or testosterone in elderly men. N Engl J Med. 2006;355(16):1647-1659. https://pubmed.ncbi.nlm.nih.gov/17050889
  14. Elraiyah T, Sonbol MB, Wang Z, et al. The benefits and harms of systemic DHEA therapy in postmenopausal women: a systematic review and meta-analysis. J Clin Endocrinol Metab. 2014;99(10):3536-3542. https://pubmed.ncbi.nlm.nih.gov/25279572
  15. Leowattana W. DHEAS as a new diagnostic tool. Clin Chim Acta. 2004;341(1-2):1-15. https://pubmed.ncbi.nlm.nih.gov/14967151
  16. Azziz R, Carmina E, Chen Z, et al. Polycystic ovary syndrome. Nat Rev Dis Primers. 2016;2:16057. https://pubmed.ncbi.nlm.nih.gov/27510637
  17. ACOG Committee Opinion No. 803: Androgen Insufficiency in Women. Obstet Gynecol. 2020;136(6):e170-e180. [https://www.acog.org/clinical/clinical-guidance/committee-opinion/articles/2020/11/androgen-insufficiency-in-women](https://www.acog.org/clinical/clinical-guidance/committee-opinion/articles/2020/11/